跳到正文
原文
MedTech Dive 器械媒体· Susan Kelly·· 2026-09-28精选AI 评分77

FDA发布手术机器人上市前审查草案指南

FDA issues draft guidance for surgical robots

AI 导读

FDA发布了一份50页的草案指南,详细列出了机器人辅助手术器械上市前提交的评估标准,涵盖系统稳定性、延迟、运动控制、网络安全及临床数据等内容。指南指出FDA将于12月2日至3日举办两天公开研讨会,重点讨论具备自主或远程操作能力的手术机器人;Evercore ISI分析师认为该指南为行业提供了具体的审批路径,有助于降低临床证据负担。

推荐理由

原文明确指出FDA发布50页草案以解决此前审批框架的模糊性,读者可据此判断机器人手术器械的合规路径变化。

正文

An article from site logo

Dive Brief

A two-day public workshop on evaluating robotic surgery systems with autonomous or remote capabilities is also on the agency’s agenda, as telesurgery advances globally.

Published Sept. 28, 2026

By

Clinicians assist during a robot-assisted surgery while the surgeon works from the console in the background.

Clinicians assist in a procedure performed with Johnson & Johnson's Ottava robotic system as the surgeon works from a console. Courtesy of Johnson & Johnson

This audio is auto-generated. Please let us know if you have feedback.

Dive Brief:

  • The Food and Drug Administration last week released a draft guidance document spelling out what the agency wants to see in premarket submissions for robotically assisted surgical devices.
  • The 50-page document details criteria for system stability and latency, instrument motion and position control, visualization, software, wireless technology, cybersecurity, sterilization, clinical data, labeling, training and more.
  • The agency also said it will hold a two-day public workshop on Dec. 2-3 focused on evaluating the benefits and risks of robotic medical devices with autonomous or remote teleoperation capabilities.

Dive Insight:

The FDA’s draft guidance comes as a steady stream of new robotic surgery systems enters the marketplace, many to compete with longtime leader Intuitive.

The agency’s upcoming workshop on robotic devices with remote teleoperation capabilities signals that telesurgery is on the FDA’s radar as more remote procedures are performed globally.

The FDA defines surgical robots as teleoperated, software-controlled systems that have technologies and subassemblies designed to assist clinicians in using instruments to perform open, minimally invasive or endoluminal procedures. Robotic technologies may contain some level of automated functions, the agency said.

Evercore ISI analysts, in a research note, called the draft guidance a positive for the industry because it lays out a specific pathway for FDA approval, compared with a “prior framework that had some ambiguity.” Without a standardized framework, software and cybersecurity in particular can become hurdles, they noted.

The document also helps companies planning to launch newer versions of existing systems by detailing how to show substantial equivalence compared with predicate devices, they said. The guidance provides clarity on specific clinical endpoints for different procedures as well as a pathway for umbrella procedure approval that would cover a more complex procedure within the same category. “This will minimize the clinical evidence burden to some extent,” the analysts wrote.

The FDA is seeking comments on the draft guidance by Nov. 24.

来源:MedTech Dive 器械媒体 · medtechdive.com